Plant · Scientific monograph
Coffea arabica
Arabica coffee
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Coffee-pulp research, Metabolic research
Research overview
Historical use
Coffee fruit has long been consumed as a beverage; the clinical evidence listed here concerns a specific aqueous coffee-pulp product, not brewed coffee or green/roasted beans [1,2].
Modern research context
A placebo-controlled study examined a named aqueous coffee-pulp extract in adults with obesity and elevated LDL. It is exploratory, product-specific research and does not establish effects for coffee beans, beverages, or other pulp products [1].
Adverse effects
The small, time-limited trial does not establish uncommon or long-term adverse effects. Safety of the EFSA-assessed food ingredient cannot be generalized to other preparations [1,2].
Contraindications
Distinguish pulp extract from coffee beverages, beans, leaves and multi-ingredient supplements. Medicinal use and interactions depend on caffeine and product composition; no universal safety profile follows from these sources [1,2].
Clinical and phytochemical data
Used part
Aqueous coffee-fruit pulp extract in the cited RCT; not roasted/green beans [1].
Primary active compounds
Mechanism of action
The RCT measures lipid-related outcomes and does not establish a mechanism for coffee pulp [1]. The cited human studies do not characterize an active compound or establish constituent-specific activity.
Pharmacokinetics
Absorption
Human PK for the coffee-pulp extract was not established in the cited RCT abstract [1].
Distribution
Not characterized.
Metabolism
Not characterized for the named pulp product.
Excretion
Not characterized.
Safety and interactions
Drug interactions
No clinical interaction study for the named pulp product identified in the cited sources.
Toxicity
Long-term medicinal toxicity is not established; the EFSA opinion is limited to a defined food ingredient [2].
Special precautions
Pregnancy
Medicinal-use safety during pregnancy is not established by the cited sources.
Lactation
Medicinal-use safety during lactation is not established by the cited sources.
Hepatic impairment
No impairment-specific evidence identified.
Renal impairment
No impairment-specific evidence identified.
Sources and references
- [1] Supawan Buranapin et al. Potential lipid-lowering effects of Coffea arabica pulp extract product in hyperlipidemia-obese subjects: a randomized double-blind placebo-controlled trial. Frontiers in Nutrition. 2026;13:1755054. PMID: 41909045. DOI: 10.3389/fnut.2026.1755054.
- [2] EFSA Panel on Food Additives and Flavourings et al. Safety evaluation of pectin-rich extract derived from Coffea arabica as food additive. EFSA Journal. 2026;24(1):e9852. PMID: 41608242. DOI: 10.2903/j.efsa.2026.9852.